F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)
Recruitment status was Not yet recruiting
Florbetapir F 18 is an experimental radioactive drug that may allow doctors to image changes in the brain using a PET (Positron Emission Tomography) scanner. The purpose of this study is to evaluate the imaging characteristics of, Florbetapir F 18 (also known as 18F-AV-45) in patients who have previously undergone bleeding in their brains. Florbetapir F 18 binds to amyloid-ß peptide (Aß) that accumulates in the brains of patients with bleeding. These accumulations are called amyloid plaques and when extensive are labeled cerebral amyloid angiopathy (CAA). Florbetapir F 18 sticks to the amyloid plaques in the brain and emits a low level of gamma rays which can be detected by a PET camera.
MRI detected microbleeds have been identified as markers of clinically silent hemorrhage from bleeding-prone vessels. Another imaging marker of vessel damage and risk of bleeding is the spot sign (SS). Finally, certain genetic signatures (ApoE genotype) have been shown to be associated with Aß deposition in the brain or predispose patients to higher risks of bleeding. This research study will explore the interactions of these factors and understand the physiology of intracerebral bleeding.
Cerebral Amyloid Angiopathy
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)|
- Type of Bleed [ Time Frame: 2-3 weeks ] [ Designated as safety issue: No ]Patients will be divided into micro- and macro- bleeders based on MRI detected microhemorhage pattern. Processing of each patient will take 2-3 weeks.
- Spot Sign Status [ Time Frame: 2-3 weeks ] [ Designated as safety issue: No ]They will be further subdivided by spot sign status into positive or negative.
- Amyloid uptake [ Time Frame: 2-3 weeks ] [ Designated as safety issue: No ]
- ApoE genotype [ Time Frame: 2-3 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||August 2011|
|Estimated Study Completion Date:||August 2012|
|Estimated Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
CAA positive microbleeders
Cerebral amyloid angiopathy (CAA) positive microbleeders
|probable CAA macrobleeders|
|CAA negative microbleeders|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01382849
|Contact: Raphael Jakubovic||416-480-6100 ext email@example.com|
|Contact: Richard Aviv||416-480-6100 ext firstname.lastname@example.org|
|Sunnybrook Health Sciences Centre||Not yet recruiting|
|Toronto, Ontario, Canada, M4N 3M5|
|Principal Investigator:||Richard Aviv||Sunnybrook Health Sciences Centre|